1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993; 129:92–96.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011; 7:803–815.
![crossref](/image/icon/bnr_ref_cross.gif)
3. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006; 55:9–16.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996; 15:250–257.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol. 1998; 134:874–876.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006; 55:1–8.
7. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008; 128:35–44.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010; 88:60–68.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Singalavanija S, Limpongsanurak W. Stevens-Johnson syndrome in Thai children: a 29-year study. J Med Assoc Thai. 2011; 94:Suppl 3. S85–S90.
10. Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012; 92:62–66.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Indian J Dermatol Venereol Leprol. 2012; 78:734–739.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Kim HI, Kim SW, Park GY, Kwon EG, Kim HH, Jeong JY, Chang HH, Lee JM, Kim NS. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med. 2012; 27:203–210.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC. A marker for Stevens-Johnson syndrome...: ethnicity matters. Pharmacogenomics J. 2006; 6:265–268.
14. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428:486.
15. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008; 49:2087–2091.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, Dave DM, Goyal RK. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009; 75:579–582.
17. Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011; 50:221–224.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010; 51:2461–2465.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, Ikezawa Z, Iijima M, Shiohara T, Hashimoto K, Kamatani N, Nakamura Y. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011; 20:1034–1041.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, Kang HR, Park HW, Cho SH, Park SH, Min KU, Chang YS. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011; 97:190–197.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005; 102:4134–4139.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009; 19:704–709.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008; 9:1617–1622.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang IJ, Cho SH, Min KU, Kim SH, Lee KW. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011; 21:303–307.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Chan R. Sexually transmitted infections in Asia and the Pacific--an epidemiological snapshot. Sex Transm Infect. 2011; 87:Suppl 2. ii14–ii15.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol. 2007; 7:324–330.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001; 15:1843–1848.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012; 13:49–54.
29. Kannenberg SM, Jordaan HF, Koegelenberg CF, Von Groote-Bidlingmaier F, Visser WI. Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study. QJM. 2012; 105:839–846.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000; 115:149–153.
31. von Wild T, Stollwerck PL, Namdar T, Stang FH, Mailänder P, Siemers F. Are Multimorbidities Underestimated in Scoring Systems of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Like in SCORTEN? Eplasty. 2012; 12:e35.
32. Hague JS, Goulding JM, Long TM, Gee BC. Respiratory involvement in toxic epidermal necrolysis portends a poor prognosis that may not be reflected in SCORTEN. Br J Dermatol. 2007; 157:1294–1296.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Wei CH, Chung-Yee Hui R, Chang CJ, Ho HC, Yang CH, Lin YJ, Chung WH. Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol. 2011; 21:930–937.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013; 69:187.e1–187.e16.
35. Weinand C, Xu W, Perbix W, Lefering R, Maegele M, Rathert M, Spilker G. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of mortality risk for causative agents. Burns. 2013; pii: S0305-4179(13)00085-5.
![crossref](/image/icon/bnr_ref_cross.gif)
36. Cartotto R, Mayich M, Nickerson D, Gomez M. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res. 2008; 29:141–146.
![crossref](/image/icon/bnr_ref_cross.gif)
37. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns. 1996; 22:275–278.
![crossref](/image/icon/bnr_ref_cross.gif)
38. Ying S, Ho W, Chan HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns. 2001; 27:372–375.
![crossref](/image/icon/bnr_ref_cross.gif)
39. Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenous immunoglobulins in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol. 2013; doi:
10.1111/bjd.12607.
40. Thong BY, Mirakian R, Castells M, Pichler W, Romano A, Bonadonna P, Diana D, Kowalski M, Yanez A, Lleonart R, Sanchez-Borges M, Demoly P. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. World Allergy Organ J. 2011; 4:257–270.
![crossref](/image/icon/bnr_ref_cross.gif)
41. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998; 282:490–493.
![crossref](/image/icon/bnr_ref_cross.gif)
42. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003; 139:26–32.
43. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003; 139:33–36.
44. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012; 167:424–432.
![crossref](/image/icon/bnr_ref_cross.gif)
45. Zhu QY, Ma L, Luo XQ, Huang HY. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. J Burn Care Res. 2012; 33:e295–e308.
46. Gaitanis G, Spyridonos P, Patmanidis K, Koulouras V, Nakos G, Tzaphlidou M, Bassukas ID. Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin. Dermatology. 2012; 224:134–139.
![crossref](/image/icon/bnr_ref_cross.gif)
47. Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maître B, Revuz J, Bagot M, Roujeau JC. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010; 163:847–853.
![crossref](/image/icon/bnr_ref_cross.gif)
48. Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol. 2013; 79:686–692.
![crossref](/image/icon/bnr_ref_cross.gif)
49. Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Roujeau JC. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol. 2012; 167:555–562.
![crossref](/image/icon/bnr_ref_cross.gif)
50. O'Donoghue JM, Céspedes YP, Rockley PF, Nigra TP. Skin biopsies to assess response to systemic corticosteroid therapy in early-stage TEN: case report and review of the literature. Cutis. 2009; 84:138–140. 161–162.
51. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol. 1991; 25:778–786.
52. Gubinelli E, Canzona F, Tonanzi T, Raskovic D, Didona B. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009; 36:150–153.
![crossref](/image/icon/bnr_ref_cross.gif)
53. Wojtkiewicz A, Wysocki M, Fortuna J, Chrupek M, Matczuk M, Koltan A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol. 2008; 88:420–421.
54. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol. 2005; 116:923–924.
55. Bamichas G, Natse T, Christidou F, Stangou M, Karagianni A, Koukourikos S, Chaidemenos G, Chrysomallis F, Sombolos K. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher. 2002; 6:225–228.
![crossref](/image/icon/bnr_ref_cross.gif)
56. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998; 352:1586–1589.
![crossref](/image/icon/bnr_ref_cross.gif)
57. Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011; 18:e121–e133.
58. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007; 26:123–129.
59. Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, Heng WJ. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007; 62:527–531.
![crossref](/image/icon/bnr_ref_cross.gif)
60. López-García JS, Rivas Jara L, García-Lozano CI, Conesa E, de Juan IE, Murube del Castillo J. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis. Ophthalmology. 2011; 118:265–271.
![crossref](/image/icon/bnr_ref_cross.gif)
61. Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009; 145:157–162.
![crossref](/image/icon/bnr_ref_cross.gif)
62. Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, Ikezawa Z, Hashimoto K, Kinoshita S. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009; 116:685–690.
![crossref](/image/icon/bnr_ref_cross.gif)
63. Prabhasawat P, Tesavibul N, Karnchanachetanee C, Kasemson S. Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye. J Ocul Pharmacol Ther. 2013; 29:372–377.
![crossref](/image/icon/bnr_ref_cross.gif)
64. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye (Lond). 2005; 19:846–853.
![crossref](/image/icon/bnr_ref_cross.gif)
65. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol. 2007; 91:1048–1053.
![crossref](/image/icon/bnr_ref_cross.gif)
66. Ciralsky JB, Sippel KC, Gregory DG. Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Ophthalmol. 2013; 24:321–328.
![crossref](/image/icon/bnr_ref_cross.gif)
67. Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol. 2006; 97:419–428.
![crossref](/image/icon/bnr_ref_cross.gif)
68. Petersen KD, Kronborg C, Gyrd-Hansen D, Dahl R, Larsen JN, Løwenstein H. Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires. Allergy. 2008; 63:284–291.
69. Salvilla SA, Panesar SS, Patel S, Rader T, Muraro A, Roberts G, de-Blok BF, Dubois A, Sheikh A. Disease-specific health-related quality of life (HRQL) instruments for food allergy: protocol for a systematic review. Clin Transl Allergy. 2013; 3:15.
![crossref](/image/icon/bnr_ref_cross.gif)
70. Baiardini I, Braido F, Fassio O, Calia R, Giorgio WC, Romano A. Development and validation of the Drug Hypersensitivity Quality of Life Questionnaire. Ann Allergy Asthma Immunol. 2011; 106:330–335.
![crossref](/image/icon/bnr_ref_cross.gif)
71. Butt TF, Cox AR, Lewis H, Ferner RE. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. Drug Saf. 2011; 34:319–328.
72. Roujeau JC. Stevens-Johnson Syndrome and toxic epidermal necrolysis: improving the support to victims. Drug Saf. 2013; 36:145–146.
73. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, Tai CT, Wu SL, Lu CH, Hsu YC, Yu HY, Ro LS, Lu CT, Chu CC, Tsai JJ, Su YH, Lan SH, Sung SF, Lin SY, Chuang HP, Huang LC, Chen YJ, Tsai PJ, Liao HT, Lin YH, Chen CH, Chung WH, Hung SI, Wu JY, Chang CF, Chen L, Chen YT, Shen CY. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011; 364:1126–1133.
![crossref](/image/icon/bnr_ref_cross.gif)
74. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358:568–579.
![crossref](/image/icon/bnr_ref_cross.gif)
75. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, Chu CY, Chen YT. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010; 11:349–356.
![crossref](/image/icon/bnr_ref_cross.gif)
76. Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology. 2012; 79:1259–1267.
![crossref](/image/icon/bnr_ref_cross.gif)
77. Hung SI, Chung WH. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology. 2013; 80:1621.
![crossref](/image/icon/bnr_ref_cross.gif)
78. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess. 2005; 9:1–157. iii–iv.
![crossref](/image/icon/bnr_ref_cross.gif)
79. Shi YW, Min FL, Qin B, Zou X, Liu XR, Gao MM, Wang Q, Zhou JQ, Liao WP. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? Basic Clin Pharmacol Toxicol. 2012; 111:58–64.
![crossref](/image/icon/bnr_ref_cross.gif)
80. Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013; 93:153–158.
![crossref](/image/icon/bnr_ref_cross.gif)
81. Calogiuri G, Nettis E, Di Leo E, Foti C, Ferrannini A, Butani L. Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules. Inflamm Allergy Drug Targets. 2013; 12:19–28.
![crossref](/image/icon/bnr_ref_cross.gif)
82. Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HW, Chang YS, Cho SH, Min KU, Kang HR. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011; 26:3567–3572.
![crossref](/image/icon/bnr_ref_cross.gif)